Clinical Trial Update: A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib plus valproic acid in chronic myelogenous leukemia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• VALPROIC ACID (Valproic acid)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: WITHDRAWN